Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2022-10-31 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
第九届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the first meeting of the ninth Supervisory Board of Shenzhen Haiwang Bioengineering Co., Ltd. It details the election of the chairman of the Supervisory Board and confirms the meeting procedures and voting results. There is no financial data, no mention of annual or interim reports, no audit information, and no indication of a shareholder meeting or voting results related to dividends or general meetings. The document is a corporate governance announcement related to board or supervisory committee changes. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear content and context.
2022-10-31 Chinese
关于公司董事局、监事会完成换届选举及聘任高级管理人员和证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the completion of the re-election of the company's board of directors, supervisory board, and the appointment of senior management and securities affairs representatives. It includes comprehensive information about the composition of the new board, committees, supervisory board members, and senior management personnel, along with their qualifications and resumes. The document does not contain financial statements or financial performance data but focuses on governance and management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is substantial and contains detailed personnel information, not just a brief announcement or a report publication notice.
2022-10-31 Chinese
第九届董事局第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the first meeting of the ninth board of directors of Shenzhen Haier Bioengineering Co., Ltd. It details the election of the chairman, vice chairman, and members of various board committees. The content focuses on board and management changes and does not contain financial data, audit information, or other report types. The document length is short (1264 characters), and it is clearly an announcement of board decisions rather than a full report or presentation. Therefore, it fits the category of Board/Management Information (MANG).
2022-10-31 Chinese
2022年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 third extraordinary general meeting of shareholders of Shenzhen Haier Bioengineering Co., Ltd. It includes voting results for the election of board members and supervisors, details on attendance, voting methods, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official results of shareholder votes at a general meeting, including election outcomes and approval of director and supervisor allowances. There is no financial data, no presentation materials, no management discussion, no audit or legal proceeding updates, and no report publication notice. The document fits the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA) as it officially reports the voting results from a shareholder meeting.
2022-10-31 Chinese
2022年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司2022 年第三季度报告" which translates to "Shenzhen Haiwang Bioengineering Co., Ltd. 2022 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2022. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. There is no indication that this is an announcement or a certification; it is the actual report itself. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the supervisory board meeting resolution approving the company's 2022 third quarter report. It states the meeting date, voting results, and confirms the report's compliance and accuracy. The document itself does not contain the financial data or the full report but is a formal announcement of the supervisory board's approval of the quarterly report. The document length is short (605 characters), and it serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement related to the quarterly report approval, not the report itself (IR).
2022-10-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.